Common commercial cosmetic products induce arthritis in the DA rat. by Sverdrup, B et al.
Common Commercial Cosmetic Products Induce Arthritis in the DA Rat
B. Sverdrup,1 L. Klareskog,1 andS. Kleinaut'2
1Department of Medicine, Rheumatology Unit, Karolinska Institute, Stockholm, Sweden; 2Department of Pathology, University Hospital,
Uppsala, Sweden
Manydifferent agents, incding mineri oil and silicone, have the capacityto act as immunoloajal
adjuvants i.e., theycancontribute to theactivaton ofthe immunestem. Some adjumants, inldud-
big mineraloil, asre known to induce arthritis in certain stain of-rats after malinjecton or
pcutaneous The aim of.this suy was to dete ifcommon commeial cosmetic
prd&coaningmaloilcouldinducearthrtisinth higWysuseptbeDA(DarkAgouti) rat
Intadmalinjecrionoffiveoutofeightassyedcosmeticproductswithoutfiurte additv resulted
iart iswith:synovitis.Oneofthepr indiedaveryag:garth ,whichhaddelined
after 5-9weeks.'Whenthisproductw also edforariae uponpcutaneousadminis-
trtion, it induced a mild and transitat atitisin 5 our of 10 DA rats, whera control animals
showedno linici involvement Noarthitic reactnws sen inrats afterperoralfeed-
lug with themost togenproutorbyintra plic tionofFreunds adjuvants. Silicone
gelimplnts in DA rats did not cause arthritis. We con de that mineral oiLs induded in common
commercially aaila;blelproductsrantheradj n ties and area it ic in thepresendy
investigated arthriis-prone ratstrain. Thereisyetnoevidence thatmineraloils present in mics
maycon tbu o arthritis inhuman but we suggest that this paesion should besubject tofiuther
investigation. 1&ywon& adjuvants, arthritis, cosmeticproducts, mineraloil,rats,siliconegel.
Environ:HealthPe.rspe 106.27-32 (1998) (Online 2Juary19981
.hnip://.e4ntl.niehs.ni& s/18/1Rl06pi27-32 dvepwpabssracbtml
Adjuvants that contain microbial-derived
molecules have long been known to have a
capacityto induce arthritis notonlyin exper-
imental animals, mainly rats (1), but most
probablyalso in humans in conjunction with
administration of adjuvants used in cancer
therapy (2,3). An interesting extension of
these older findings was made relatively
recentlywhen it was demonstrated that non-
immunogenic adjuvants, such as mineral oil
with no content ofmicrobial products, could
also, by themselves, induce arthritis in cer-
tain arthritis-susceptible strains ofrats after a
single intradermal or subcutaneous injection
at the root ofthe tail (4).
These findings raised the question of
whether substances with adjuvant proper-
ties might also contribute to arthritis devel-
opment when administered in ways that are
common in humans, and it was indeed
demonstrated that mineral oils, without any
additives, could also induce arthritis in
Dark Agouti (DA) rats after percutaneous
application (5).
We have as yet no empirical evidence
that mineral oils or other nonimmunogenic
adjuvants have any proarthritogenic activity
in humans. However, connective tissue dis-
ease has been suggested to occur following
cosmetic mammary augmentation with sili-
cone or injections of paraffin oil (human
adjuvant disease) (6), although later epi-
demiological investigations have failed to
support this (7). Therefore, we considered
it of interest to investigate if pure mineral
oils and also some ofthe many mineral oil-
containing commercial products intended
for skin care could induce arthritis in the
rat experimental system.
In this study we have selected a few
commercially available mineral-oil contain-
ing skin products and vaginal gel, which
are in common use in Sweden, and investi-
gated to what extent these products, as well
as two pure mineral oils (constituents of
cosmetics and ingredients in food), could
induce arthritis in DA rats after intrader-
mal, percutaneous, or peroral administra-
tion. To investigate possible arthritogenici-
ty by intravaginal application, we used
Freund's adjuvants. The development of
arthritis was studied clinically as well as
histologically, and the production of
autoantibodies was determined. Likewise,
we wanted to investigate the arthritogenic
potential of a silicone gel used in human
mammary implants because silica or relat-
ed substances such as silicone have been
reported to have adjuvant'properties (8).
Materials and Methods
Animals. DA and Lewis rats of both sexes
were used at 2-5 months of age. The ani-
mals were maintained in the animal unit at
Karolinska Hospital (Stockholm, Sweden).
They were obtained from inbred colonies
from the Central Institute for Laboratory
Animal Breeding (Hannover, Germany) and
from Harlan (Zeist, Netherlands). Routine
screening for pathogens gave negative results
for Sendai virus, coronavirus, pneumonia
virus, and Mycoplasma pulmonis. The rats
had free access to water and rodent chow
(R36; B&KUnviversal Ltd, Hull, England).
Treatments. Freund's complete adjuvant
(FCA), composed of mineral oil, mycobac-
teria, and an emulsifying agent (Arlacel A),
and Freund's incomplete adjuvant (FIA),
composed ofmineral oil andArlacel A, were
obtained from Difco Laboratories (Detroit,
MI). Two different mineral oils dassified as
medicinal white oil for food, pharmaceuti-
cal, and cosmetic use, Medicway M 68
(Statoil, Stavanger, Norway) and Kaydol
(Witco Corporation, Greenwich, CT), were
also studied.
Seven different commercial skin products
containing possible immunological adjuvants
(especially mineral oils) were bought in cos-
metic shops and pharmacies: three skin
creams (ACO, Helosan, and Margaret
Astor), two body lotions (Nivea and LdB),
and two baby oils (Natusan and Barnangen).
The exact composition ofthe products is not
publidy available. However, the fat content
(with different shares mineral oil and veg-
etable oils) is in general about 30-40% for
skin cream (ointment) and about 20% for
skin lotion. For baby oil, the general mineral
oil content is 80%. Compositions ofthe dif-
ferent productswere given on the packages:
*ACO Skin Cream (ACO Likemedel,
Stockholm, Sweden): butylhydroxitoluen,
ethanol, glycerol 8%, peanut oil andparaf-
fin, metagin (E218), propagin (E216),
monostearin, stearic acid, stearol, tri-
etanolamin,fragrnce, water).
* Helosan Ointment (EWOS, Helsingborg,
Sweden): paraffin liq, cetanolum, stear-
olum, POE-stearat glycerylstearat, glyc-
erolum, propagin (E216), polyhexam-
ethylenbiguanid HCL, eucalyptolum,
aquapurificata.
*MargaretAstor, Collagen Liposome- Skin
Care/Collagen Creme Active (Margaret
AstorAG, Mainz, Germany): concentrate
with additive of elastine, lecithin, and
avocado oil.
* Nivea Milk Emulsion (BeiersdorfAG,
Hamburg, Germany): water demin.,
paraffin oil, isohexadecane, isopropyl
palmitate, vaseline, PEG-40 sorbitan
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peroleate, polyglyceryl-3 diisostearate,
glycerine, magnesium sulfate, alumini-
um stearates, cetyl palmitate, glyceryl
lanolate (neoceril), lanolin alcohol, phe-
noxyethanol, methyldibromo glutaroni-
trile, fragrance.
*LdB Creme Lotion Rich (Elida Farbege.
Malmo, Sweden): water, mineral oil,
propylene glycol, glycerinmonostearate,
glycerindistearate, alkalistearate, petro-
latum, potassium cetyl phosphate,
cetearylalcohol, fragrance, carbomer
941, methylparaben, lecithin liposomes
with tissue respiratory factor, toco-
pherol, proline, evening primrose oil,
sodium hydroxide, propylparaben, car-
bomer 940, C.I.21230.
*Natusan Baby Oil Uohnson & Johnson
AB, Sollentuna, Sweden): mineral oil,
cetearyl octanoate, trilaureth-4 phosphate.
*Barnangen Baby Oil (Barnangen AB,
Ekero, Sweden): paraffin oil, cetyl alco-
hol, thyme oil.
One vaginal gel rich in mineral oil con-
tent was also analyzed. Replens Hormone
Free Vaginal Gel (Maropack AG, Zell
Switzerland; water, glycerine, mineral oil,
polycarbofil, carbopol 934P, and sorbinic
acid) was bought in alocalpharmacy.
Silicone gel and a silicone elastomer
envelope were taken from an unused sterile
silicone mammary implant (McGhan
Medical Corporation, Santa Barbara, CA).
Routes ofAdministration
Intradermal injection. One single intrader-
mal (ID) injection of400 or 500 1d ofthe
different skinproducts, vaginalgel, orminer-
al oils was given at the base ofthe tail. ACO
and Helosan skin creams were diluted 1:1
with phosphate-buffered saline (PBS) before
injection. As a positive control of arthritis
development, one group ofrats received 200
pl FIA ID. One group of rats, the negative
controls, received no injection. The animals
were thereafter examined for dinical mani-
festations for 1-3 months (Table 1).
Percutaneous application. In the shoul-
der region of DA rats, a 2-cm2 area was
shaved and lightly abrased with sandpaper
during ether anesthesia. Abrasion was per-
formed to accumulate inflammatory cells
in the skin and thereby facilitate uptake of
the oil. The abrasion was repeated twice
more during the treatment period at 3-4
day intervals. Natusan Baby Oil was
applied directly onto the skin in a volume
of400 gil, and this treatment was repeated
10 times during 12 days. Control animals
were shaved and abrased only. The animals
were thereafter examined for dinical mani-
festations for at least 1 month (Table 2).
Intravaginal application. Under ether
anesthesia, each female DA rat received one
intravaginal application of 500 il FCA fol-
lowed by five applications of 500 pl FIA
over 12 days. The animals were thereafter
examined for clinical manifestations for 3
months (Table 2).
Peroralfeeding. Kaydol mineral oil (500
pl) was given to DA rats by sound feeding
under ether anaesthesia daily for 5 days. The
animals were thereafter examined for dinical
manifestations for7months (Table 2).
Subcutaneous implant. A silicone breast
implant was cut into 1.6-3.5 g pieces and
implanted subcutaneously into a skin pocket
in the back of each of 10 DA rats under
Brietal anesthesia. In addition, one rat
received a piece of the silicone envelope
implanted in the same manner. The weight
ofthe implant was adjusted to the rats body
weight (6.8-16.4 g/kg body weight, i.e.,
0.68-1.64%) to resemble theweight ofa sil-
icone breast implant in women (-1.40%).
Two control ratsweresham operated.
Examination and evaluation ofjoint
inflammation. Animals were examined daily
during the second week for clinical manifes-
tations and onset of arthritis and thereafter
two to three times every week during the
first month. Severity of arthritic joints was
scored using a scale of 1-4 for each paw
(maximum possible score of 16 per rat) (S).
In the first series, evaluation of some cos-
metic products, positive and negative con-
trols were observed blind (Table 1). The rats
were coded and the results were read blind
by two independent observers. In the fol-
lowing series, some ofthe observations were
read blind by one independent observer.
All rats were followed for at least 1 month
after initial treatment.
Skin irritation test. Six DA rats were
shaved in the shoulder region under Brietal
anesthesia, and 400 pl Natusan Baby oil
was administered onto the skin, covered
with a cotton compress, and fixed with a
bandage for 24 hr. Two control rats were
shaved and only covered with a bandage.
Macroscopic inspection of the dermis was
performed after 24 hr, and skin biopsies
Table 1. Incidence of arthritis in rats after a single intradermal injection of different skin care products,
vaginal gel, or mineral oils
Mean Maximum
Rat Dose Arthritis day of arthritic Follow-up
strain Sex Product (pI) incidence onset score days
DA Skin cream
M ACO 400 0/7 _ 38
F Helosan 500 0/10 - - 84
2M,8F MargaretAstor 500 2/10 19 8 84
Body lotion
M Nivea 500 3/10 21 6 83
6M,4F LdB 500 2/10 22 12 83
Baby oil
M Natusan 400 1/7a 15 12 38
M Natusan 500 4/10 16 12 29
M Barnangen 500 4/10 24 8 83
Vaginal gel
3M,4F Replens 400 0/7a - - 38
Mineral oil
F Medicway 500 6/10 21 12 90
F Kaydol 500 9/10 15 13 90
M FIA 200 4/4a 13 16 38
M None - 0/6a - - 38
Lewis F Kaydol 500 0/10 - - 50
Abbreviations: DA, Dark Agouti; M, male, F,female.
aObservations made blindly.
Table 2. Arthritic incidence in DA rats following different routes of administration of mineral oils or
implant ofsilicone
Mean Maximum
Arthritis day of arthritic Follow-up
Sex Administration Product Dose incidence onset score months
M PC Natusan 400 pi x 10 5/10 13 4 1
M Control - 0/10 - - 1
2M,8F P0 Kaydol 500 pi x 5 0/10 - - 7
F Invag FCANFIA 500pi x6 0/10 - - 3
M Implant Silicone gel - 0/10 - - 6
Silicone envelope - 0/1 - - 6
Sham operation - 0/2 - - 6
Abbreviations: M, male, F,female; PC, percutaneous; PO, per oral; Invag, intravaginal.
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from the treated area were taken and snap
frozen. After cryostat sectioning and stain-
ing with hematoxylin and eosin (H&E),
microscopic evaluation ofskin biopsies was
performed.
Blood analysis. Retroorbital bleeding
was performed under ether anesthesia at
different time points after different treat-
ments. Serum and plasma samples were
stored at -20°C until assay.
Fibrinogen levels in plasma were deter-
mined in rats treated with silicone, measured
by the Thrombin method (10) with the
Stago reagents kit (Diagnostica Stago,
Asnieres, France), andread inanautolyzer.
Examination for autoantibodies was
performed without knowledge ofthe treat-
ment given.
Indirect immunofluorescence (IIF) was
used to screen for organ-specific autoanti-
bodies (11). Briefly, seradiluted 1:10 in PBS
from treated and control animals were incu-
bated on cryostat sections ofrat kidney and
stomach. After rinsing in PBS, sections were
incubated with fluorescein isothiocyanate
(FITC)-conjugated goat-antirat (GAR) IgG
antibodies (Jackson Laboratories, West
Grove, PA) at adilution of1:40.
Analysis of antinuclear antibodies
(ANAs) by human epithelial cell (HEp-2,
Immunoconcepts, Sacramento, CA) IIF was
also performed. Sera diluted 1:40 in PBS
were incubated on HEp-2 cells followed by
incubation with FITC-GAR IgG. The
mounted slides were viewed with a fluores-
cence microscope.
To detect rheumatoid factor (RF), sera
were assayed for IgM antibodies to rat IgG in
an enzyme-linked immunosorbent assay
(ELISA). Briefly, microtiterplateswerecoated
overnight at 40Cwith 50 pl/well of 10 pg/ml
rat IgG in PBS. Dilutions ofsera and wash-
ings were made in PBS containing 0.05%
Tween-20. All tests were carried out in qua-
druplicate. Levels ofIgM antibodies in a sam-
ple were quantified with goat-antirat IgG
antibodies conjugated to alkaline phosphatase
Jackson Laboratories). Thesubsequentquan-
tification of bound enzyme was performed
with apara-nitrophenol-containing substrate
in a spectrophotometer. Samples having an
absorbance greater than the mean + 2 stan-
dard deviations (SD) ofnormal rats, read at
405 nm, weredefined aspositive.
Serawereassayed for antibodies to type II
collagen (CII) in an ELISA (9). Briefly,
microtiter plates were coated overnight at
40C with 50 p1/well of 10 pg/ml rat CII in
PBS. Dilutions of sera and washings were
made in PBS containing 0.05% Tween-20.
All tests were carried out in duplicate. Levels
ofanti-CII antibodies in asample werequan-
tified with GAR IgG antibodies conjugated
to alkaline phosphatase Jackson Labora-
tories). The subsequent quantification of
bound enzyme was performed with a para-
nitrophenol-containing substrate buffer in a
spectrophotometer. Concentrations ofanti-
CII antibodies were determined by compari-
sonwith an affinity-purified rat anti-CII anti-
bodyofknown activity. Positivesampleswere
defined as having an absorbance greater than
themean + 2 SD ofnormal DArats.
Histology. Ankle joints of Natusan-
treated animals (ID) were fixed in 4%
phosphate-buffered formaldehyde and
decalcified with 14% EDTA in 0.36 M
NaOH for 4 weeks. After dehydration,
clearing, and impregnation, the tissues
were embedded in paraffin blocks, sec-
tioned, and stained with H&E.
Lymph nodes and spleens from the
same animals were fixed in formaldehyde,
embedded in paraffin, sectioned, and
stainedwith H&E.
Results
Effects ofintrade-alinjection. Five out of
seven assayed skin products induced pol-
yarthritis in the DA rat (Table 1). The inci-
dence varied from 10 to 40%, and rats of
both sexes were affected. Mean day of
arthritis onset was between 13 and 24 days
after injection. The arthritis often started
symmetrically in the hind paws and later
also affected the front paws. The severity of
arthritis reached its maximum 2-3 weeks
after injection and became less severe dur-
ing the following weeks, without any
detectable signs of ankylosis or functional
disorders. Duration of the arthritis was
from 5 to almost 9 weeks.
Intradermal injection with skin creams
with high viscosity or with the vaginal gel
14 11 1w 1 | Kaydsoln
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Figure 1. Comparison of mean arthritic scores in
groups of arthritic DA rats injected intradermally
with Freund's incomplete adjuvant (FIA; 200 pi; n =
4), Natusan Baby Oil (500 pi; n = 4), and Kaydol
mineral oil (500 pi; n =9).
(Replens) did not induce any arthritis.
However, development ofulcerswas observed
at the injection site of animals receiving
Replens.
A high incidence ofarthritis was record-
ed in DA rats injected with the medicinal
mineral oils Medicway and Kaydol (Table
1). Six out of 10 DA rats developed arthritis
after injection with Medicway. Kaydol
induced very aggressive arthritis in 90% of
the DA rats. Lewis rats injected with Kaydol
in the same manner did not develop any
arthritis. Animals treated with Natusan Baby
Oil or Kaydol mineral oil exhibited similar
clinical pictures of arthritis as the positive
control group receiving FIA (Fig. 1).
Effects ofpercutaneous application. One
of the products, Natusan Baby Oil, which
was arthritogenic by intradermal injection,
was also tested for its capacity to induce
arthritis after repeated percutaneous (PC)
application on abrasedskin. Bythis route, the
DA rats developed joint inflammations that
were, in general, mild and transient and pre-
dominantly affected single joints in the
forepaws. The mean day ofonset ofarthritis
was 13 days after start oftreatment, and the
maximum arthritic scorewas 4. The duration
ofthe arthritis was 4-6 days (Fig. 2). Control
rats did not develop any signs of arthritis.
Skin irritation tests with Natusan Baby Oil
gave no macroscopic changes ofthe skin, and
microscopicevaluationperformedonbiopsies
from Natusan-treated skin did not show any
signsofinflammation (datanotshown).
Effects oforalsoundfeeding. One ofthe
medicinal mineral oils, Kaydol, which is per-
mitted as a food additive and which exhibit-
ed arthritogenicity in DA rats when injected
intradermally, was also investigated for its
potential arthritogenicity after oral sound
feeding to DA rats. However, no arthritic
reactionwas detected in theseanimals during
an observation periodof7 months (Table 2).
Effects ofintravaginal application.
Arthritogenicitywas assesed byadminstration
12 _ _
U
4
2
Daysafterstarteftreatment
Figure 2. Mean arthritic scores in arthritic rats
after repeated percutaneous treatment with
Natusan Baby Oil.
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via the intravaginal route. DA rats were first
treated with one intravaginal application of
FCAfollowed byFIAfive times over 12 days.
No arthritis was recorded during a follow-up
of3 months.
Effects ofsilicone implants. Silicone
implants or the silicone envelope did not
cause any arthritis in DA rats. The animals
were observed for a 6-month period (Table
2). Elevated fibrinogen levels were observed
in silicone treated animals on days 6 and
17 after implantation ofsilicone; however,
these levels had decreased to those ofsham
operated animals a month later.
Histopathology. Histology of arthritic
joints at days 21, 25, and 33 postinjection
from animals injected ID with Natusan Baby
Oil verified arthritic reactions with infiltra-
tion of mononuclear cells, synovitis, and
marginal erosions (Fig. 3). Tendinitis and
tendovaginitis were also evident (Fig. 4).
Histology oflymph nodes (Fig. 5) from the
same animal showed an increased number of
cells, diffuse germinal centres, and large
round vesicles, probably disseminated oil
droplets in the marginal zone (Fig. 6). The
spleen was cell rich and vesicles were not evi-
dent.
Serologicalanalysis. ANAs assayed by IIF
of tissue sections were negative in DA rats
treated with Natusan or Barnangen babyoils,
Margaret Astor cream, Kaydol, or FCA/FIA
bydifferent treatmentregimes (Table3).
However, ANAs analyzed by HEp-2
cells showed positive Golgi or centromere
antibodies in 3/10 DA rats administered
Kaydol orally. In 4/11 silicone-implanted
animals, positive Golgi antibodies could be
detected. One sham operated rat also had
Golgi antibodies.
RF was positive in 5/10 DA rats orally
treated with Kaydol, but was also positive
in some animals treated intradermally with
Barnangen Baby Oil or Margaret Astor
skin cream. In one control rat, positive RF
could be detected.
CII antibodies were detected in 4/10
animals previously injected with Margaret
Astor skin cream containing collagen, oils,
and liposomes. One of the, CII-positive
animals had arthritis.
Discussion
The aim of this study was to investigate if
common commercially available cosmetic
products that contain mineral oils or medic-
inal mineral oils can induce arthritis in the
particularly arthritis-susceptible DA rat
strain. The results dearly demonstrated that
several ofthese products can induce arthritis
with many similarities to the previously
described oil-induced arthritis after intrader-
mal administration; in addition, at least one
of them can induce arthritis after percuta-
neous application on skin that had been
moderatelyirritatedbymechanical means.
A first conclusion ofthese results is that
mineral oils added to thecommercial cosmet-
ic products have retained their arthritogenic
Figure 3. Arthritic hind paw showing synovitis and infiltration of mononuclear Figure 4. Tendinitis in arthritic hind paw 33 days after intradermal injection
cells 33 days after intradermal injection with baby oil. Original magnification x80. with baby oil. Original magnification x80.
Figure 5. Histology of a lymph node 25 days after intradermal injection with
baby oil showing an increased number of cells, diffuse germinal centers, and
large, round vesicles. Original magnification x32
Figure 6. Histology of a lymph node 33 days after intradermal injection with
baby oil showing large, round vesicles, probably disseminated oil droplets in
the marginal zone. Original magnification x200.
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Table 3. Analysis of autoantibody production in rats treated with cosmetic products, mineral oils, or sili-
cone implants
Blood
Admin- Arthritis sample ANA in ANA in
Treatment istration incidence day (pi) CII rattissue HEp-2 RF
Natusan ID 4/10 20 ND 0/7 0/7 0/8
Natusan PC 5/10 19 ND 0/10 0/10 0/4
PC control None 0/10 19 ND 0/10 0/10 1/6
Barningen ID 4/10 56 ND 0/10 0/10 2a/l0
M. Astor ID 2/10 54 4/10 0/10 0/10 1/9
Kaydol ID 9/10 67 0/10 0/10 0/10 0/10
Kaydol P0 0/10 80 0/10 0/10 3b110 5/10
FCA/FIA Invag 0/10 114 ND 0/4 0/4
Normal None 0/10 0/10 0/12 0/12 0/5
Silicone SC implant 0/11 54 0/11 0/11 4C/1 1 0/11
Sham operation None 0/2 54 0/2 0/2 1C/2 0/2
Abbreviations: pi, post injection; ND, not done; CIl, collagen 11; ANA, antinuclear antibodies; HEp-2, human epithelial
cells; RF, rheumatoid factor; ID, intradermal; PC, percutaneous; PO, per oral; Invag, intravaginal; SC, subcutaneous;
FCA/FIA, Freund's complete and incomplete adjuvants.
aArthritic.
bContained one centromere and two Golgi.
Ccontained Golgi.
potentials in the DA rats, even after being
mixed with the many additional substances
induded in the various commercial products.
The variation in arthritogenicity evident
between various commercial products indi-
cates that such modifications may occur, and
wedo not knowifthe quantitative content of
mineral oil in a commercial product is the
only factor determining arthritogenicity in
thepresent experimental system.
A second conclusion is that at least one
of the mineral oil-containing products
intended for application on skin can induce
arthritis in the DA rat after being applied
by a method similar to that recommended
for use by humans (percutaneously). We
carried out this provocation on mildly
abrased skin, as this procedure has previous-
ly been shown to enhance the arthritogenic
effects ofpercutaneous exposure ofmineral
oil present in FIA (5). The product that has
the capacity to induce polyarthritis after
either intradermal or percutaneous exposure
still did not induce any irritative reaction
measurable by macroscopic or microscopic
investigation. This is in line with our previ-
ous observation that the effects of these
nonimmunogenic adjuvants occur mainly
in the regional lymph nodes (12,13) in
which the adjuvants cause activation of T
lymphocytes, which have a capacity to sub-
sequently induce arthritis (14). This also
means, however, that such substances
appear to be able to induce arthritis, at least
after being applied to irritated skin, without
giving rise to any types of local irritative
reaction ofthe kind that are used to screen
commercial cosmetic products for potential
irritation or other adverse effects.
The pathogenic mechanisms responsible
for arthritis induction after exposure to
nonimmunogenic adjuvants, either in the
form of Freund's incomplete adjuvant or
present in cosmetic products, are still not
completely known, but it has been shown
that several different genes, both within and
outside the major histocompatibility com-
plex, are involved (15) and that T lympho-
cytes are needed for disease development;
oil-induced arthritis can be blocked by in
vivoadministration ofanti-T-cell antibodies
(16). Whether the adjuvants trigger activa-
tion ofT cells with a specificity for certain
autoantigens (e.g., from cartilage) or
whether the T cells cause arthritis by some
more unspecified actions is as yet not
known. The relative lack ofanti-collagen II
antibodies in most ofthe experiments may
indicate that autoimmunity to collagen II is
not ofmajor importance in this context.
It is difficult to draw any firm conclu-
sions from the relative lack of antinuclear
antibodies and the presence of RF in the
serum oftwo arthritic rats and some orally
fed animals. It has previously been demon-
strated that the DA rat has a high tendency
for production of RF, also after systemic
immunizations; this feature may obviously
be related to a general high capacity ofthe
DA rat to acquire several different autoim-
mune diseases, i.e. not only arthritis but
also encephalitis, neuritis, and others (17).
In the present study, only administra-
tion via the skin caused arthritis, whereas
peroral or intravaginal applications did not
give rise to any disease symptoms. This does
not mean that administration of adjuvants
via these routes can be excluded as a risk
factor for arthritis development in the DA
rat; we have not tested the effects of oral
administration ofadjuvants in conjunction
with inflammation of the gut caused by
some other agent, for example, thereby par-
alleling the situation with abrased skin.
Silicone gel from breast implants has
been suggested to be an adjuvant (8).
However, silicone gel alone did not appear
to be arthritogenic in our experiments, in
agreement with recent reports (18).
A major final question is obviously to
what extent our present findings in the par-
ticularly arthritis-susceptible DA rat has
any relevance for the situation in humans
as to a potential arthritogenic capacity of
any of the presently investigated cosmetic
products. So far, there is no epidemiologi-
cal or clinical evidence favoring a role of
adjuvant-containing cosmetic products in
the development of arthritis or any other
inflammatory diseases. On the other hand,
few studies have been performed that
would have allowed any such conclusions
to be drawn, particularly if a risk for such
adjuvant arthritis to occur in humans
should be strictly limited to individuals car-
rying genes which confer high arthritis sus-
ceptibility. It should also be noted that cur-
rent product testing methods for local irri-
tation in animals are probably not relevant
in the identification of products with
arthritogenic capacities.
There is consequently a need for well-
performed studies, which include genetic
techniques for identification of subgroups
ofpotentially arthritis-susceptible individu-
als, to study the possibility that some com-
mercial cosmetic products may have a
capacity to contribute to arthritis induction
in humans in some individuals and in cer-
tain situations. In the meantime, further
mechanistic and genetic studies in the
experimental systems may be able to define
the pathophysiological mechanisms of this
remarkable capacity of both nonimmuno-
genic adjuvant oils and several commercial
products containing such oils to induce a
polyarthritis with many similarities to
inflammatoryjoint disease in humans.
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